Abstract Library

#4497 Complex management of a long-term gastrinoma survivor with multimodal treatment approaches

Introduction: The prognosis of pancreatic gastrinomas is influenced by tumour burden, extent of metastasis, and treatment response, with 5-year survival rates ranging from 20% to 40%. Treatment for well-differentiated tumours typically include locoregional therapies, long-acting somatostatin analogues, molecular targeted agents, radionuclides, and chemotherapy.

Conference:

Presenting Author: Puscasu A

Authors: Puscasu A, Miron M, Croitoru A,

Keywords: gastrinoma, neuroendocrine tumour, long survival, complex management,

#4445 Pancreatico-duodenal gastrinomas: Surgical management and late results – 50 years' experience in a single centre

Introduction: Gastrinomas are one of the less frequent and elusive variety of neuroendocrine tumours (NET) of the upper digestive tract and pancreas, clinically expressed with a Zollinger-Ellison syndrome (ZES), possibly associated to a Multiple Endocrine Neoplasia type 1 (MEN1).

Conference:

Presenting Author:

Authors: Milanetto A, Veronese E, de Carlo E, Pasquali C,

Keywords: gastrinoma, men1, net,

#4354 Analysis of gastric NENS in the Czech neuroendocrine tumour registry (2009-2024)

Introduction: Czech Neuroendocrine Tumour Registry is collecting data of NEN patients and their treatment since 2009. We have already analysed SI NENs, pancreatic and thymic NENs. Now we focused on analysis of gastric NENs.

Conference:

Presenting Author:

Authors: Barkmanova J, Sedlackova E,

Keywords: registry, gastric neuroendocrine neoplasia,

#4007 Inactivation of PHLDA3 gene leading to tumorigenesis of pancreatic neuroendocrine tumors and its molecular mechanisms

Introduction: The molecular mechanism underlying the tumorigenesis of sporadic pancreatic neuroendocrine tumors (PNETs) is largely unknown. Our previous studies showed that loss of heterozygosity (LOH) at chromosome 1q31 (including PHLDA3 gene) was frequently found in sporadic PNETs (2005 insulinoma and 2003 gastrinoma, respectively).

Conference:

Presenting Author: Song Y

Authors: Song Y, Tong W, Wang Z, Chen Y,

Keywords: pancreatic neuroendocrine tumor, PHLDA3, tumorigenesis, prognosis,

#3955 Development of clinically representative patient-derived organoid models for diverse G1/G2 gastroenteropancreatic neuroendocrine tumors

Introduction: While gastroenteropancreatic neuroendocrine tumors (GEP-NETs) grow slowly, they are incurable when reaching advanced stages. The characteristic slow growth of GEP-NETs results in the scarcity of clinically relevant models that has hindered our comprehension of GEP-NET biology and pathology, leading to limited progress in systemic therapies of GEP-NET treatment.

Conference:

Presenting Author:

Authors: Zuo X, Liu Y, Maxwelll J, Halperin D, Dasari A,

Keywords: gastroenteropancreatic neuroendocrine tumors, patient-derived organoids, Dox-controlled genetic modifications, characterization,